AbbVie (ABBV) announced that a new 6-month 45mg Lupron Depot strength has received Health Canada approval for the treatment ...

SCHAUMBURG, Ill., June 02, 2025--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Leuprolide Acetate ...

This open-label study evaluated the efficacy and safety of a new leuprolide acetate 45 mg 6-month depot formulation in 151 men with prostate cancer who received 2 intramuscular injections administered ...

Cipla has launched Leuprolide Acetate Injection Depot 225mg The product was approved by the United States Food and Drug Administration US FDA based on a New Drug Application NDA submitted under the ...

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Leuprolide ...

Cipla Limited and its wholly owned subsidiary Cipla USA Inc., has announced the launch of leuprolide acetate injection depot 22.5mg. The product was approved by the United States Food and Drug ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the ...

MUMBAI, India and WARREN, N.J., Nov. 29, 2022 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) and its wholly owned subsidiary Cipla USA Inc. (hereafter referred to as 'Cipla'), today ...

The efficacy and side-effect profile of ulipristal acetate as compared with those of leuprolide acetate for the treatment of symptomatic uterine fibroids before surgery are unclear. In this ...